Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection

Mark R. Schleiss; Nigel Bourne; David I. Bernstein

doi:10.1086/379839

Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection

Mark R. Schleiss, Nigel Bourne, David I. Bernstein

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

DNA vaccines expressing the guinea pig cytomegalovirus (GPCMV) homologs of the glycoprotein B (gB) and UL83 proteins were evaluated for protection against congenital GPCMV infection. After 4 doses of DNA administered by epidermal (gene gun) route, all guinea pigs developed enzyme-linked immunosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody. Dams were challenged with 1 × 10⁴ plaque-forming units of GPCMV in the third trimester. Preconception vaccination with gB did not decrease overall pup mortality, although, within the gB-vaccine group, pup mortality was lower among dams with high ELISA responses. Preconception maternal vaccination with gB vaccine significantly reduced congenital transmission in liveborn pups. In contrast, UL83 vaccine had no significant effect on pup mortality or vertical transmission of GPCMV. Virus load was significantly lower in infected pups born to gB- and UL83-vaccinated dams than in infected pups born to control dams. These data support the concept that subunit gB vaccination may be useful in protecting against CMV-induced disease.

Original language	English (US)
Pages (from-to)	1868-1874
Number of pages	7
Journal	Journal of Infectious Diseases
Volume	188
Issue number	12
DOIs	https://doi.org/10.1086/379839
State	Published - Dec 15 2003
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/379839

Cite this

Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection. / Schleiss, Mark R.; Bourne, Nigel; Bernstein, David I.
In: Journal of Infectious Diseases, Vol. 188, No. 12, 15.12.2003, p. 1868-1874.

Research output: Contribution to journal › Article › peer-review

@article{805146a3dea044c5b27622b709907d89,

title = "Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection",

abstract = "DNA vaccines expressing the guinea pig cytomegalovirus (GPCMV) homologs of the glycoprotein B (gB) and UL83 proteins were evaluated for protection against congenital GPCMV infection. After 4 doses of DNA administered by epidermal (gene gun) route, all guinea pigs developed enzyme-linked immunosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody. Dams were challenged with 1 × 104 plaque-forming units of GPCMV in the third trimester. Preconception vaccination with gB did not decrease overall pup mortality, although, within the gB-vaccine group, pup mortality was lower among dams with high ELISA responses. Preconception maternal vaccination with gB vaccine significantly reduced congenital transmission in liveborn pups. In contrast, UL83 vaccine had no significant effect on pup mortality or vertical transmission of GPCMV. Virus load was significantly lower in infected pups born to gB- and UL83-vaccinated dams than in infected pups born to control dams. These data support the concept that subunit gB vaccination may be useful in protecting against CMV-induced disease.",

author = "Schleiss, {Mark R.} and Nigel Bourne and Bernstein, {David I.}",

note = "Funding Information: Received 7 May 2003; accepted 3 July 2003; electronically published 9 December 2003. Financial support: National Institutes of Health (grants AI-65289 and HD38416-01); March of Dimes (basic research grants 6-FY98/99-0416 and FY01-226). Reprints or correspondence: Dr. Mark Schleiss, Div. of Infectious Diseases, Children{\textquoteright}s Hospital Research Foundation, 3333 Burnet Ave., Cincinnati, OH 45229 (schlm0@chmcc.org).",

year = "2003",

month = dec,

day = "15",

doi = "10.1086/379839",

language = "English (US)",

volume = "188",

pages = "1868--1874",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection

AU - Schleiss, Mark R.

AU - Bourne, Nigel

AU - Bernstein, David I.

N1 - Funding Information: Received 7 May 2003; accepted 3 July 2003; electronically published 9 December 2003. Financial support: National Institutes of Health (grants AI-65289 and HD38416-01); March of Dimes (basic research grants 6-FY98/99-0416 and FY01-226). Reprints or correspondence: Dr. Mark Schleiss, Div. of Infectious Diseases, Children’s Hospital Research Foundation, 3333 Burnet Ave., Cincinnati, OH 45229 (schlm0@chmcc.org).

PY - 2003/12/15

Y1 - 2003/12/15

N2 - DNA vaccines expressing the guinea pig cytomegalovirus (GPCMV) homologs of the glycoprotein B (gB) and UL83 proteins were evaluated for protection against congenital GPCMV infection. After 4 doses of DNA administered by epidermal (gene gun) route, all guinea pigs developed enzyme-linked immunosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody. Dams were challenged with 1 × 104 plaque-forming units of GPCMV in the third trimester. Preconception vaccination with gB did not decrease overall pup mortality, although, within the gB-vaccine group, pup mortality was lower among dams with high ELISA responses. Preconception maternal vaccination with gB vaccine significantly reduced congenital transmission in liveborn pups. In contrast, UL83 vaccine had no significant effect on pup mortality or vertical transmission of GPCMV. Virus load was significantly lower in infected pups born to gB- and UL83-vaccinated dams than in infected pups born to control dams. These data support the concept that subunit gB vaccination may be useful in protecting against CMV-induced disease.

AB - DNA vaccines expressing the guinea pig cytomegalovirus (GPCMV) homologs of the glycoprotein B (gB) and UL83 proteins were evaluated for protection against congenital GPCMV infection. After 4 doses of DNA administered by epidermal (gene gun) route, all guinea pigs developed enzyme-linked immunosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody. Dams were challenged with 1 × 104 plaque-forming units of GPCMV in the third trimester. Preconception vaccination with gB did not decrease overall pup mortality, although, within the gB-vaccine group, pup mortality was lower among dams with high ELISA responses. Preconception maternal vaccination with gB vaccine significantly reduced congenital transmission in liveborn pups. In contrast, UL83 vaccine had no significant effect on pup mortality or vertical transmission of GPCMV. Virus load was significantly lower in infected pups born to gB- and UL83-vaccinated dams than in infected pups born to control dams. These data support the concept that subunit gB vaccination may be useful in protecting against CMV-induced disease.

UR - http://www.scopus.com/inward/record.url?scp=0346059312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346059312&partnerID=8YFLogxK

U2 - 10.1086/379839

DO - 10.1086/379839

M3 - Article

C2 - 14673766

AN - SCOPUS:0346059312

SN - 0022-1899

VL - 188

SP - 1868

EP - 1874

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 12

ER -

Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV Infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this